ImmuCell Corporation
NASDAQ:ICCC · NASDAQ Capital Market
+$0.19 today
Vol 0.03M · Avg 0.03M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $6.8M |
| Receivables | $2.7M |
| Inventory | $8.7M |
| Other Current | $681.2K |
| Total Current Assets | $18.9M |
| PP&E (Net) | $25.1M |
| Goodwill | $95.6K |
| Other Non-current | $34.2K |
| Total Non-current Assets | $25.2M |
| Total Assets | $44.1M |
Analysis
Selected assets total $44.1M for Latest. The largest visible component is PP&E (Net) at $25.1M, about 56.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.8M +1.3% | $3.8M +284.0% | $978.7K -83.1% | $5.8M -43.1% | $10.2M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 +100.0% | -$468 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $3.4M -10.3% | $3.8M +74.4% | $2.2M +21.4% | $1.8M -33.8% | $2.7M | $533.8M | $399.4M | -$1.7B |
| Inventory | $9.3M +30.3% | $7.1M -9.0% | $7.8M +29.4% | $6.0M +95.4% | $3.1M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $31.4K | $0 -100.0% | $39.7K | $0 | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $16.9M +12.6% | $15.0M +31.2% | $11.5M -18.0% | $14.0M -14.0% | $16.3M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $0 -100.0% | $29.9M -7.0% | $32.1M +4.9% | $30.6M +9.4% | $28.0M | $1.2B | $1.5B | $687.8M |
| Goodwill | $95.6K +0.0% | $95.6K +0.0% | $95.6K +0.0% | $95.6K +0.0% | $95.6K | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 -100.0% | $19.1K -50.0% | $38.2K -33.3% | $57.3K -25.0% | $76.4K | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $25.5M +76296.6% | $33.4K -42.1% | $57.7K -24.8% | $76.6K +193.4% | $26.1K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $25.6M -14.9% | $30.1M -7.1% | $32.3M +4.8% | $30.9M +9.5% | $28.2M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $42.5M -5.7% | $45.1M +3.0% | $43.8M -2.3% | $44.9M +0.9% | $44.5M | $13.3B | $11.9B | $10.6B |
| Account Payables | $796.3K -15.6% | $943.6K +6.3% | $887.7K +12.4% | $790.0K +6.0% | $745.0K | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $1.6M +7.5% | $1.5M +4.8% | $1.4M +37.5% | $1.0M +28.0% | $812.2K | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 -100.0% | $3.1K -37.6% | $4.9K +128.4% | $2.1K | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $0 | $0 -100.0% | $306.8K | $0 | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $4.0M -9.8% | $4.4M +5.1% | $4.2M +36.6% | $3.1M +21.2% | $2.5M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $7.5M -17.2% | $9.0M -14.2% | $10.5M +14.7% | $9.2M +10.4% | $8.3M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $11.5M -12.7% | $13.2M -9.9% | $14.6M +28.1% | $11.4M +22.0% | $9.4M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $15.5M -12.0% | $17.6M -6.6% | $18.8M +29.9% | $14.5M +21.8% | $11.9M | $14.7B | $3.7B | $9.6B |
| Common Stock | $910.6K +0.7% | $904.2K +15.7% | $781.4K +0.0% | $781.4K +0.0% | $781.4K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$15.2M -7.3% | -$14.2M -18.0% | -$12.0M -92.7% | -$6.2M -66.7% | -$3.7M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 +100.0% | -$0 -86.7% | -$0 +48.3% | -$0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 -100.0% | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $27.1M -1.7% | $27.5M +10.1% | $25.0M -17.7% | $30.4M -6.7% | $32.6M | $9.1B | $7.7B | $3.3B |
| Total Debt | $13.2M -12.6% | $15.1M -9.5% | $16.7M +33.7% | $12.5M +21.5% | $10.3M | $724.2M | $410.6M | $399.4M |
| Net Debt | $9.4M -17.2% | $11.3M -27.8% | $15.7M +134.9% | $6.7M +7411.8% | $89.0K | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Century Therapeutics, Inc.
NASDAQ:IPSC
$196.58M
Equillium, Inc.
NASDAQ:EQ
$107.81M
Fortress Biotech, Inc.
NASDAQ:FBIO
$100.49M
OS Therapies Incorporated
AMEX:OSTX
$81.06M
Cue Biopharma, Inc.
NASDAQ:CUE
$70.99M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$69.75M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$63.36M
Coeptis Therapeutics, Inc.
NASDAQ:COEP
$55.98M
Genenta Science S.p.A.
GNTA
$32.55M
Senti Biosciences, Inc.
SNTI
$24.58M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ICCC have?
ImmuCell Corporation (ICCC) reported $3.81M in cash and equivalents in fiscal 2025.
How much debt does ICCC carry?
ImmuCell Corporation (ICCC) reported $13.19M of total debt, with net debt of $9.39M.
Explore More
Continue the stock analysis
Jump to another research area for this company.